| Original language | English (US) |
|---|---|
| Pages (from-to) | 171-173.e1 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 74 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2016 |
ASJC Scopus subject areas
- Dermatology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Botulinum toxin for depression : Does patient appearance matter? / Reichenberg, Jason S.; Hauptman, Aaron J.; Robertson, Henry T. et al.
In: Journal of the American Academy of Dermatology, Vol. 74, No. 1, 01.01.2016, p. 171-173.e1.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Botulinum toxin for depression
T2 - Does patient appearance matter?
AU - Reichenberg, Jason S.
AU - Hauptman, Aaron J.
AU - Robertson, Henry T.
AU - Finzi, Eric
AU - Kruger, Tillman H C
AU - Wollmer, M. Axel
AU - Magid, Michelle
N1 - Funding Information: Disclosure: Dr Magid received a research grant from the Brain and Behavior Institute, National Alliance for Research on Schizophrenia and Depression Young Investigator award, to fund one of the studies on which these data are based (grant number 17648). The grant went to Seton Family of Hospitals, which then provided salary support to Dr Magid for that research. After completion and as a result of the study, Dr Magid became a consultant with Allergan in November 2012 to discuss study findings. Dr Reichenberg's spouse (Dr Magid) became a consultant with Allergan in November 2012. Dr Kruger received honoraria for talks from Servier and Lundbeck. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a member of an advisory board with Allergan. Dr Wollmer has received financial support for research through his institution, Asklepios Hamburg GmbH. He also received honoraria for talks from Merz, Novartis, Lundbeck, and Eli Lilly. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a consultant and a member of an advisory board with Allergan. Dr Hauptman has received financial support for research through his institution for a study unrelated to this subject. Dr Finzi has received a patent to treat depression with BTA. Dr Robertson has no conflicts of interest to declare. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
UR - http://www.scopus.com/inward/record.url?scp=84953377329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953377329&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2015.08.051
DO - 10.1016/j.jaad.2015.08.051
M3 - Article
C2 - 26702796
AN - SCOPUS:84953377329
VL - 74
SP - 171-173.e1
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 1
ER -